Performance of Two Silicone Hydrogel Toric Contact Lenses - Full Text View

Purpose

Evaluation of the clinical performance of two toric contact lenses in a 2-week, single masked (subject), daily wear, randomized, bilateral, parallel group study.

Condition	Intervention
Vision Correction	Device: senofilcon A toric Device: balafilcon A toric

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment
Official Title:	Multi-Center Evaluation Of Two Silicone Hydrogel Toric Contact Lenses

Resource links provided by NLM:

MedlinePlus related topics: Eye Wear

U.S. FDA Resources

Further study details as provided by Vistakon:

Primary Outcome Measures:

Lens Orientation [ Time Frame: 1 minute after insertion ] [ Designated as safety issue: No ]
Proportion of eyes with lens orientation within 5 degrees of optimal
Lens Stability [ Time Frame: 10-15 minutes after insertion ] [ Designated as safety issue: No ]
Lens stability is measured as the amount of rotation induced from blink after the lens has settled.
Subjective Comfort [ Time Frame: 2 weeks of lens wear ] [ Designated as safety issue: No ]
Subjective comfort was derived from a weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response. >0 = comfortable, < 0 = uncomfortable. Combined measures from Week 1 and Week 5.

Secondary Outcome Measures:

Time to Fit Lens [ Time Frame: after lens insertion ] [ Designated as safety issue: No ]
Time required for the optometrist to fit the lens.
Subjective Lens Vision [ Time Frame: measured at 1 and 2 weeks ] [ Designated as safety issue: No ]
A weighted combined score calculated from individual vision-related questions asked on a 1-5 scale: 1 = most negative response to 5 = most positive response was used to derive vision outcomes. >0 = satisfactory vision, < 0 = unsatisfactory vision. Analysis is performed on combined 1 week and 2 week data.
Overall Corneal Staining [ Time Frame: After 2 weeks use ] [ Designated as safety issue: No ]
National Eye Institute 0-3 Scale: Grade 0 = Normal, Grade 1 = Mild, superficial stippling, Grade 2 = Moderate, punctuate staining including superficial abrasion of the cornea, Grade 3 = Severe, abrasion or corneal erosion, deep corneal abrasion or recurrent erosion.

Enrollment:	276
Study Start Date:	February 2008
Study Completion Date:	May 2008
Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: senofilcon A toric senofilcon A, daily wear, toric contact lens worn for two weeks	Device: senofilcon A toric silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement) Other Name: ACUVUE OASYS
Active Comparator: balafilcon A toric balafilcon A, daily wear, toric contact lens worn for two weeks	Device: balafilcon A toric silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement) Other Name: PureVision Toric

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Be between 18 and 45 years of age.
Sign Written Informed Consent (See separate document).
Be an existing successful daily wear toric soft contact lens.
Require a visual correction in both eyes (monovision or uniocular fitting is NOT allowed).
Does not require presbyopic correction (can read J1 @ normal reading distance).
Have a sphere requirement in the range -1.00 and -5.00D (-5.25D refractive)
Have refractive astigmatism between 0.75D and 2.50D in both eyes.
Achieve visual acuity of 20/30 or better in each eye with spherical distance correction.
Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
- No amblyopia.
- No evidence of lid abnormality or infection.
- No conjunctival abnormality or infection.
- No clinically significant slit lamp findings (i.e. stromal edema, vascularisation, infiltrates or abnormal opacities).
- No other active ocular disease.

Exclusion Criteria:

Requires concurrent ocular medication.
Clinically significant (Grade 3 or 4) corneal stromal haze, corneal vascularisation, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
Corneal staining Grade 3 in more than one region.
Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately prior to enrolment for this study.
Abnormal lacrimal secretions.
Pre-existing ocular irritation that would preclude contact lens fitting.
Keratoconus or other corneal irregularity.
Polymethyl methacrylate (PMMA) or Rigid Gas Permeable (RGP) lens wear in the previous 8 weeks
Extended lens wear in last 3 months.
Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
Diabetic.
Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
Pregnancy, lactating or planning a pregnancy at the time of enrolment.
Participation in any concurrent clinical trial or in last 60 days.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00638846

Hide Study Locations

Locations

United States, Arkansas
Camp Eye Care Clinic
North Little Rock, Arkansas, United States, 72116
United States, California
James R. Dugue, O.D.
Mission Viejo, California, United States, 92691
United States, Colorado
Executive Park Eye Care
Colorado Springs, Colorado, United States, 80909
United States, Florida
Dr. Ted Brink and Associates
Jacksonville, Florida, United States, 32256
United States, Kansas
Grene Vision Group
Neodesha, Kansas, United States, 66757
United States, Missouri
Advanced Eyecare, PC
Raytown, Missouri, United States, 64133
United States, New Jersey
Dr. James Brobst
Florence, New Jersey, United States, 08518
United States, New York
Fine Eye Care Associates
Rochester, New York, United States, 14623
United States, Ohio
Warren Ophthalmology Associates
Warren, Ohio, United States, 44484
United States, Pennsylvania
Selden Eyecare LLC
Kittanning, Pennsylvania, United States, 16201
Nittany Eye Associates
State College, Pennsylvania, United States, 16801
United States, Rhode Island
Dr. David W. Ferris and Associates
Warwick, Rhode Island, United States, 02886
United States, South Dakota
Dr. Larry Menning
Chamberlain, South Dakota, United States, 57325-0490
United States, Texas
Wishnow-Sugar Vision Group
Katy, Texas, United States, 77450
United States, Utah
Dr. William Bogus
Salt Lake City, Utah, United States, 84106
United States, Virginia
Midlothian Optometric Center
Midlothian, Virginia, United States, 23113
The Eye Specialists, Ltd.
Virginia Beach, Virginia, United States, 23455
United States, Washington
The Eye & Contact Lens Clinic
Bremerton, Washington, United States, 98310
United States, Wisconsin
Matus Eyecare
Franklin, Wisconsin, United States, 53132

Sponsors and Collaborators

Vistakon

Investigators

Study Director:

Graeme YOung, MPhil PhD

More Information

No publications provided

Responsible Party:	Vistakon
ClinicalTrials.gov Identifier:	NCT00638846 History of Changes
Other Study ID Numbers:	CR-0801, CTOR-501
Study First Received:	March 10, 2008
Results First Received:	June 18, 2010
Last Updated:	September 28, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Vistakon:

toric contact lenses
vision
comfort
toric fit characteristics
slit lamp findings

ClinicalTrials.gov processed this record on May 22, 2013